Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 57Leukemia 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 20Congenital Abnormalities 19Prostatic Neoplasms 18Lymphoma, Non-Hodgkin 14Leukemia, Erythroblastic, Acute 14Leukemia, Myelomonocytic, Acute 13Leukemia, Monocytic, Acute 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Follicular 12Leukemia, Megakaryoblastic, Acute 12Myelodysplastic Syndromes 10Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 5Lymphoma, Mantle-Cell 5Breast Neoplasms 5Anemia, Refractory, with Excess of Blasts 5Neoplasms 4Leukemia, Biphenotypic, Acute 4Burkitt Lymphoma 4Blast Crisis 4Ovarian Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Eosinophilic, Acute 3Leukemia, Basophilic, Acute 3Hodgkin Disease 3

Interventions

Dexamethasone 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Blood Specimen Collection 4Surveys and Questionnaires 3Prednisone 3Melphalan 3Lenalidomide 3Biopsy, Fine-Needle 3fluciclovine F-18 2carfilzomib 2Positron-Emission Tomography 2Mammography 2Injections 2Immunohistochemistry 2Gemcitabine 2Cytarabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2weifuchun 1vistusertib 1venetoclax 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1ricolinostat 1pomalidomide 1phosphoribosylformylglycinamidine synthetase 1pembrolizumab 1ofatumumab 1obinutuzumab 1lortalamine 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Disease × Mitoxantrone × Clear all
NCT00143975 2010-08-12

Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

University of Ulm

Phase 2 Completed
95 enrolled
Other hematologic neoplasm

Disease, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡